文献速递胸部肿瘤

Rova-T联合纳武利尤单抗±伊匹木单抗治疗经治广泛期小细胞肺癌的1-2期研究

A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
PubMed 文献 · J Thorac Oncol · 2021-02-27

这项开放标签1-2期研究评估了靶向DLL3的抗体药物偶联物Rova-T联合纳武利尤单抗±伊匹木单抗在经治广泛期小细胞肺癌(ES SCLC)中的安全性和疗效。42例患者入组两个队列,客观缓解率30%(12/40),但所有患者均发生治疗相关不良事件,3例5级不良事件与药物相关。结论认为该联合方案虽显示抗肿瘤活性,但耐受性不佳。

要点

  • Rova-T联合纳武利尤单抗±伊匹木单抗在经治ES SCLC中客观缓解率30%。
  • 所有患者发生治疗相关不良事件,最常见为胸腔积液(48%)。
  • 3例5级不良事件与药物相关:肺炎2例、急性肾损伤1例。

核心结论

  • Rova-T联合纳武利尤单抗±伊匹木单抗在经治ES SCLC中显示抗肿瘤活性,但在所评估的剂量和给药方案下耐受性不佳。

研究设计与样本

  • 开放标签1-2期研究,纳入组织学或细胞学确诊、既往接受过两线及以上治疗的ES SCLC患者,分两个队列。
  • 队列1(n=30)接受Rova-T 0.3 mg/kg每6周一次共2周期联合纳武利尤单抗360 mg(从第4周开始两个3周周期)。
  • 队列2(n=12)接受相同剂量Rova-T联合纳武利尤单抗1 mg/kg(四个3周周期)和伊匹木单抗1 mg/kg(从第4周开始)。
  • 两队列均从第10周开始接受纳武利尤单抗480 mg每4周一次。
  • 主要目标为评估安全性和耐受性及疗效(按RECIST 1.1),疗效结果基于中心阅片数据。

主要发现

  • 共42例患者接受治疗:队列1 n=30,队列2 n=12;总体43%接受过两线及以上既往治疗。
  • 所有患者发生至少1项治疗中出现的不良事件(TEAE);41例报告研究者认为与研究药物相关的不良事件。
  • 最常见TEAE为胸腔积液(n=20,48%);最常见≥3级TEAE为贫血(n=9,21%)。
  • 3例5级TEAE被认为与研究药物相关(均在队列1):肺炎(n=2)、急性肾损伤(n=1)。
  • 客观缓解率为30%(12/40):队列1为27.6%(8/29),队列2为36.4%(4/11);均为部分缓解。

临床怎么用

  • 该联合方案在经治ES SCLC中虽显示一定抗肿瘤活性,但毒性显著,需谨慎评估获益风险。
  • 治疗期间需密切监测胸腔积液、贫血及肺炎、急性肾损伤等严重不良事件。

局限性

  • 研究为开放标签、非随机设计,样本量较小(共42例),两个队列样本量不均衡。
  • 疗效结果基于中心阅片数据,但未报告无进展生存期或总生存期等时间-事件终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This open-label, phase 1-2 study evaluated the safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune checkpoint inhibitors nivolumab plus or minus ipilimumab in previously treated extensive-stage SCLC (ES SCLC). METHODS: Patients with histologically or cytologically confirmed, previously treated (two or more lines of therapy) ES SCLC were enrolled into two cohorts. Cohort 1 received 0.3 mg/kg Rova-T (once every 6 wk for two cycles) plus 360 mg nivolumab (two 3-wk cycles beginning on week 4). Cohort 2 received the same dosage of Rova-T as cohort 1 plus 1 mg/kg nivolumab (four 3-wk cycles) and 1 mg/kg ipilimumab (beginning week 4). Both cohorts received 480 mg nivolumab every 4 weeks starting at week 10. Key objectives were to evaluate safety and tolerability and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1). The response-related results are based on centrally read data. RESULTS: A total of 42 patients received therapy: cohort 1, n = 30; cohort 2, n = 12. Overall, 43% received two or more previous lines of therapy. All patients experienced one or more treatment-emergent adverse event (TEAE); 41 patients reported AEs considered related to the study drug by the investigator. The most frequent TEAE was pleural effusion (n = 20, 48%); most common grade greater than or equal to 3 was anemia (n = 9, 21%). Three grade 5 TEAEs considered related to the study drug were reported (cohort 1): pneumonitis (n = 2), acute kidney injury (n = 1). The objective response rate was 30% (12 of 40): cohort 1, 27.6% (8 of 29); cohort 2, 36.4% (4 of 11); all partial responses. CONCLUSIONS: Despite encouraging antitumor activity in previously treated ES SCLC, combination therapy with Rova-T and nivolumab plus or minus ipilimumab was not well tolerated at the dose levels and administration schedules evaluated.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Malhotra J, Nikolinakos P, Leal T, et al. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021. PMID: 33652156. doi:10.1016/j.jtho.2021.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。